bucindolol has been researched along with Hypertension in 17 studies
*Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (70.59) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Comer, WT; Deitchman, D; Dennis, RD; Kreighbaum, WE; Matier, WL; Minielli, JL; Perhach, JL | 1 |
| Aban, IB; Ahmed, A; Ahmed, MI; de Denus, S; Desai, RV; Feller, MA; Guichard, JL; Mujib, M; White, M | 1 |
| Ackerson, L; Avins, AL; Neuhaus, J; Pressman, A; Rudd, P | 1 |
| Deedwania, P; Fagerberg, B; Ghali, J; Goldstein, S; Gottlieb, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J | 1 |
| Akman, D; Ali, I; Brendorp, B; Bruun, NE; Køber, L; Møller, J; Ottesen, M; Torp-Pedersen, C | 1 |
| Fedder, IL; Ferguson, RK; Rocci, ML; Rotmensch, HH; Soyka, L; Swanson, BN; Vlasses, PH | 1 |
| Deitchman, D; Snyder, RW | 1 |
| Oates, HF | 1 |
| Yancy, CW | 1 |
| Coull, A; Goodman, C; Rosendorff, C | 1 |
| Curzio, J; Reid, JL; Vincent, J | 1 |
| Jamieson, M; Petrie, JC; Robb, OJ; Verschueren, J; Webster, J | 1 |
| Lehtonen, A; Tanskanen, A; Temmerman, J | 1 |
| Deitchman, D; DeQuattro, V; Edmiston, WA; Foti, A; Kimura, S; Loo, R; Rigonan, K; Thien, S | 1 |
| Clementi, RA; Conner, DP; Deitchman, D; Ferguson, RK; Oren, A; Vlasses, PH | 1 |
| Lefflerová, K; Widimský, J | 1 |
| Kelman, AW; McSharry, DR; Meredith, PA; Reid, JL; Vincent, J | 1 |
2 review(s) available for bucindolol and Hypertension
| Article | Year |
|---|---|
The role of race in heart failure therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Coronary Artery Disease; Heart Failure; Humans; Hypertension; Incidence; Prognosis; Propanolamines; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Ventricular Dysfunction, Left | 2002 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetalol; Middle Aged; Pindolol; Propanolamines | 1988 |
6 trial(s) available for bucindolol and Hypertension
| Article | Year |
|---|---|
Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Propanolamines; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke Volume; Survival Rate; Treatment Outcome | 2012 |
Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST).
Topics: Adrenergic beta-Antagonists; Confidence Intervals; Double-Blind Method; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Placebo Effect; Placebos; Propanolamines; Treatment Outcome; United States | 2012 |
Importance of a history of hypertension for the prognosis after acute myocardial infarction--for the Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT) study group.
Topics: Adult; Aged; Aged, 80 and over; Denmark; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Propanolamines; Registries; Retrospective Studies; Risk Factors; Survival Rate; Vasodilator Agents | 2004 |
Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aldosterone; Blood Pressure; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Propanolamines; Renin; Vasodilator Agents | 1984 |
A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Exercise Test; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxprenolol; Posture; Propanolamines; Time Factors | 1985 |
Hemodynamic effects during rest and exercise of bucindolol in hypertensive men.
Topics: Adrenergic beta-Antagonists; Adult; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Physical Exertion; Propanolamines; Random Allocation; Regional Blood Flow; Vascular Resistance | 1987 |
9 other study(ies) available for bucindolol and Hypertension
| Article | Year |
|---|---|
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Hypertension; Indoles; Male; Propanolamines; Rats; Structure-Activity Relationship; Sympathomimetics; Vasodilator Agents | 1980 |
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Black People; Diabetic Angiopathies; Heart Failure; Humans; Hypertension; Meta-Analysis as Topic; Metoprolol; Multicenter Studies as Topic; Myocardial Infarction; Practice Patterns, Physicians'; Propanolamines; Randomized Controlled Trials as Topic | 2003 |
Beneficial effects of bucindolol in a canine model of pentobarbital-induced heart failure.
Topics: Animals; Blood Pressure; Dogs; Female; Heart Failure; Heart Rate; Hypertension; Indoles; Male; Pentobarbital; Propanolamines; Vascular Resistance | 1981 |
New antihypertensive agent (bucindolol)
Topics: Animals; Antihypertensive Agents; Hypertension; Indoles; Propanolamines; Rats | 1980 |
Short- and long-term studies of bucindolol in mild to moderate hypertension: efficacy, safety, and exercise responses.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Physical Exertion; Propanolamines; Time Factors | 1985 |
Bucindolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Creatine Kinase; Drug Administration Schedule; Heart Rate; Humans; Hypertension; Isoproterenol; Middle Aged; Norepinephrine; Phenylephrine; Posture; Propanolamines; Receptors, Adrenergic, alpha; Renin | 1985 |
Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cholesterol; Cholesterol, HDL; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Propanolamines; Triglycerides | 1987 |
Efficacy of bucindolol in systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Catecholamines; Electrocardiography; Exercise Test; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanolamines | 1987 |
The pharmacokinetics of bucindolol and its major metabolite in essential hypertension.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Propanolamines | 1985 |